Midatech Pharma Plc: Completion of pre-clinical liver cancer programme
July 26 2017 - 7:01AM
26 July 2017Midatech Pharma PLC("Midatech",
"Company" or "Group")
Completion of pre-clinical liver cancer
programme
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the
international specialty pharmaceutical company focused on
developing and commercialising products in oncology, today
announces the successful completion of its pre-clinical programme
for its wholly-owned candidate MTD119 (previously MTR104) for
advanced liver cancer.
The pre-clinical programme included three
subcutaneous or orthotopic liver cancer xenograft models treated
with the active cytotoxic compound maytansine conjugated with
Midatech's gold nanoparticle (GNP) technology.
The studies demonstrated potent anti-tumour
activity in vivo in all efficacy models. Peak reduction in tumour
growth due to MTD119 was more than six-fold (mean reduction more
than three-fold) compared to the current standard of care,
sorafenib, and with improved overall survival. The specific
targeting of maytansine to tumour cells by MTD119 also resulted in
significantly improved tolerability.
MTD119 is a targeted therapy treatment for
advanced hepatocellular carcinoma, which accounts for most liver
cancers and is the third leading cause of cancer deaths worldwide
with almost 800,000 deaths in 20151. Currently, 95% of cases are
non-curable and non-operable and median survival is less than one
year, with rare and short-lived successful outcomes with existing
forms of chemotherapy. Sorafenib (Nexavar) has projected 2018
annual sales of almost $1.5 billion2.
MTD119 will now enter formal investigational new
drug (IND) application enabling studies, with completion expected
in H1 2018. This will be followed by an expected IND
submission to the US Food and Drug Administration for first in
human studies to commence in 2018.
Commenting on the pre-clinical results, Dr
Jim Phillips, CEO of Midatech, said: "This is an important
milestone in moving our MTD119 compound towards the clinic as it
represents Midatech's first anti-cancer product using the Company's
core proprietary GNP technology platform. We are very encouraged by
the results so far and are focused on completing the formal IND
safety studies over the next six months and getting the product
into first in human studies in 2018."
1 World Health Organization cancer fact sheet,
February 2017, www.who.int/mediacentre/factsheets/fs297/en2
www.fiercepharma.com/special-report/nexavar
- Ends -
For more information, please contact:
Midatech Pharma PLCJim Phillips, CEOTel:
+44 (0)1235 841575www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated
Adviser and Broker)Corporate FinanceFreddy Crossley /
Duncan MonteithBrokingTom SalvesenTel: +44 (0)20 7886
2500
Consilium Strategic Communications (Financial
PR)Mary Jane Elliott / Ivar Milligan / Cameron StandageTel: +44
(0)20 3709 5700Email: midatech@consilium-comms.com
Westwicke Partners (US Investor
Relations)Chris BrinzeyTel: +1 339 970 2843Email:
chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC
Midatech is an international specialty
pharmaceutical company focused on oncology and other therapeutic
areas with a US commercial operation marketing four cancer care
supportive products, and co-promoting two others. Midatech's
strategy is to internally develop oncology products and collaborate
with partners in other therapy areas, and to drive growth both
organically and through strategic acquisitions. The Company's
R&D activities are supported by two breakthrough drug delivery
technologies: Q-Sphera for sustained release and our proprietary
gold nanoparticles. The Group, listed on AIM: MTPH and Nasdaq: MTP,
employs c.110 staff in four countries. For further company
information see: www.midatechpharma.com
Forward-Looking StatementCertain
statements in this press release may constitute "forward-looking
statements" within the meaning of legislation in the United Kingdom
and/or United States. Such forward-looking statements include, but
are not limited to, statements regarding the ability of Midatech to
successfully test, manufacture, produce or commercialize products
for conditions using the nanoparticle and sustained release drug
delivery platforms, and the ability for products in development to
achieve positive clinical results, and the ability to meet or
achieve timelines associated with pre-clinical studies, clinical
trials or regulatory submissions. Any forward-looking statements
are based on currently available competitive, financial and
economic data together with management's views and assumptions
regarding future events and business performance as of the time the
statements are made and are subject to risks and uncertainties. We
wish to caution you that there are some known and unknown factors
that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by
such forward-looking statements.
Reference should be made to those documents that
Midatech shall file from time to time or announcements that may be
made by Midatech in accordance with the London Stock Exchange AIM
Rules for Companies ("AIM Rules"), the Disclosure and Transparency
Rules ("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Apr 2023 to Apr 2024